PCSK9 inhibitors can reduce LDL cholesterol levels to below 50 mg/dL in patients with high cardiovascular risk.

“so the way pcsk9 inhibitor works is that it goes and tells the liver mop-up all the earlier because the LDL receptor that is there on the liver is prevented from being degraded so the LDL receptor overexpression in the liver mops up all the LDL cholesterol or the LDL lipoprotein from the circulation so in 14,000 patients the LDL levels were reduced to less than 50 milligrams per deciliter actually I think if I remember correctly the level was 33 zero now compare that about ninety to a hundred in the control crew 14,000 patients with an LDL cholesterol of 30 milligrams per deciliter”